Clinical trial
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
NCT05870748 is registered in ClinicalTrials.gov with Sutro Biopharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
- Lead sponsor
- Sutro Biopharma, Inc.
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- July 12, 2023
- Completion date
- August 26, 2025
- Enrollment
- 600 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.
epithelial ovarian cancer, fallopian tube cancer, ovarian cancer, platinum-resistant ovarian cancer, primary peritoneal cancer